Publication:

Chemotherapy response rate in seminoma and non-seminoma testicular cancer cases

Background Testicular cancer is a malignancy in the form of a solid tumor that occurs in men, with a global prevalence that has been steadily increasing. The most commonly found types are seminoma and non-seminoma, particularly among individuals aged 20-34 years. In recent decades, 9,560 new cases of testicular cancer were recorded in the United States in 2019. In Indonesia, based on data from January 1995 to December 2004, the majority of testicular cancer cases were also seminoma and non-seminoma types, with patient ages ranging from 18 to 72 years.

Methods Data analysis was performed using SPSS software version 29.0, employing univariate and bivariate analyses. Univariate analysis was used to describe the characteristics of the study samples. Ratio-scale data were described using the mean as a measure of central tendency and standard deviation (SD) as a measure of dispersion. Categorical data were described in percentages (%) and numbers (n), and presented in tables. Differences in chemotherapy response outcomes among testicular cancer patients, which are categorical data, were analyzed using bivariate analysis. Comparative tests were conducted to assess differences in the success rates of chemotherapy responses in testicular cancer patients. Both tests were considered statistically significant if they had a p<0.05.

Results Complete chemotherapy response in seminoma and non-seminoma testicular cancer was nearly similar at 66.7% and 68.8%, respectively; partial chemotherapy responses in seminoma and non-seminoma were 13.3% and 18.8%; however, progressive chemotherapy responses tended to be higher in seminoma (20.0%) than in non-seminoma (12.5%).

Conclusions The success rate of chemotherapy response in testicular cancer cases was mostly complete (67.7%), while partial and progressive responses were 16.1% each, and there was no difference in chemotherapy response between seminoma and non-seminoma tumors.